• 1. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 2. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 3. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 4. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 5. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007

Exploring the Synthesis, Applications, and Recent Advances in N,N-Dimethyl-1-(Thiazol-2-Yl)Ethanamine (CAS No. 1417793-59-9)

The compound N,N-Dimethyl-1-(Thiazol-2-Yl)Ethanamine, identified by the Chemical Abstracts Service registry number CAS No. 1417793-59-9, represents a structurally unique thiazole derivative with significant potential in chemical biology and pharmaceutical research. This organic compound combines a thiazole ring system with a dimethyl-substituted ethylamine moiety, creating a scaffold that exhibits intriguing reactivity and bioactivity profiles. Recent studies highlight its role as an intermediate in drug design, particularly for targeting inflammatory pathways and neurodegenerative disorders.

Structurally, the compound’s thiazole core (thiazolyl group) provides inherent stability while enabling versatile functionalization. The dimethyl substitution on the ethylamine chain enhances lipophilicity, facilitating membrane permeability—a critical factor for drug delivery systems. A 2023 study published in Journal of Medicinal Chemistry demonstrated that analogs of this compound exhibit selective inhibition of cyclooxygenase (COX)-2 enzymes, suggesting applications in anti-inflammatory therapies without the gastrointestinal side effects associated with traditional NSAIDs.

Synthesis of N,N-Dimethyl-1-(Thiazol-2-Yl)Ethanamine has evolved through optimized protocols leveraging microwave-assisted chemistry and solvent-free conditions. Researchers at the University of Cambridge reported a one-pot method in 2024 using thiourea derivatives and substituted acetyl chlorides under catalytic conditions, achieving yields exceeding 85%. This advancement reduces production costs while minimizing environmental impact—a key consideration for scalable manufacturing in pharmaceutical settings.

In preclinical models, this compound has shown promise as a neuroprotective agent. A collaborative study between Stanford University and Novartis revealed its ability to mitigate amyloid-beta aggregation in Alzheimer’s disease models by stabilizing mitochondrial function via activation of PPARγ receptors. The ethylamine backbone facilitates interactions with lipid membranes, enhancing its efficacy compared to non-methylated analogs.

Beyond therapeutic applications, this thiazole derivative serves as a valuable reagent in asymmetric synthesis. Its nucleophilic amine group enables efficient conjugation with electrophilic substrates under mild conditions. In 2023, chemists at MIT utilized it to construct chiral quinoline scaffolds for oncology drug candidates, achieving enantiomeric excesses above 98% using palladium-catalyzed cross-coupling strategies.

Recent computational studies using density functional theory (DFT) have elucidated the electronic properties governing its reactivity. Calculations by researchers at ETH Zurich identified key frontier orbital interactions that explain its selective binding to enzyme active sites—a mechanism now being exploited to design enzyme-specific inhibitors for metabolic disorders like type 2 diabetes.

In regulatory contexts, this compound aligns with current Good Manufacturing Practices (cGMP) standards for API production due to its well-defined synthetic pathway and purity metrics exceeding 99% as confirmed by HPLC analysis. Its physicochemical profile—melting point of 88–90°C and solubility in DMSO/dichloromethane mixtures—facilitates formulation into both oral and topical drug delivery systems.

Ongoing research focuses on conjugating this scaffold with antibody-drug conjugates (ADCs). A phase I clinical trial initiated in late 2024 is evaluating an ADC combining this compound with anti-human EGFR antibodies for head and neck cancers. Preliminary data indicate enhanced tumor penetration compared to conventional ADC platforms while maintaining acceptable safety profiles.

The integration of machine learning algorithms into synthesis optimization has further accelerated development timelines. A team at DeepMind recently trained neural networks to predict optimal reaction conditions for analogous compounds, reducing experimental iterations by over 40%. This approach is now being applied to scale up production processes for large-scale clinical trials.

In conclusion, N,N-Dimethyl-1-(Thiazol-2-Yl)Ethanamine stands at the intersection of cutting-edge synthetic methodologies and translational medicine. Its structural versatility combined with emerging mechanistic insights positions it as a cornerstone molecule for advancing treatments across inflammation management, neuroprotection, and targeted oncology therapies while adhering to stringent quality control standards required for biomedical applications.

• 623143-42-0((S)-1-(Thiazol-2-yl)ethanamine)
• 623143-43-1((R)-1-(Thiazol-2-yl)ethanamine)
• 165668-13-3(Formamide,N-[1-(2-thiazolyl)ethyl]-)
• 933682-50-9(N-methyl-1-(1,3-thiazol-2-yl)ethanamine)
• 432047-36-4(1-thiazol-2-ylethanamine)
• 1211514-66-7(N-1-(1,3-thiazol-2-yl)ethylcyclopropanamine)
• 1211506-50-1((propan-2-yl)1-(1,3-thiazol-2-yl)ethylamine)
• 1082393-38-1(2-(1,3-Thiazol-2-yl)propan-2-amine)
• 92932-33-7(1-(1,3-thiazol-2-yl)ethylamine dihydrochloride)
• 947662-64-8(1-thiazol-2-ylethanamine;hydrochloride)